新型取代吡唑类化合物作为5-羟色胺1A受体激动剂用于治疗神经精神疾病
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12.
Abstract
Provided herein are novel substituted pyrazoles as 5-HT1A agonists, pharmaceutical compositions, use of such compounds in treating neuropsychiatric diseases, and processes for preparing such compounds.
摘要
本文提供了作为5-羟色胺1A（5-HT1A）激动剂的新型取代吡唑、药物组合物、此类化合物在治疗神经精神疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.新型取代吡唑类化合物作为5-羟色胺1A受体激动剂用于治疗神经精神疾病
ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12.
2
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.新型取代内酰胺类化合物作为5-HT1A激动剂用于治疗神经精神疾病。
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
3
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
4
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
5
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular Diseases.新型哌啶取代的吡唑并嘧啶衍生物作为治疗心血管疾病的SGK1抑制剂
ACS Med Chem Lett. 2025 Apr 25;16(5):762-763. doi: 10.1021/acsmedchemlett.5c00217. eCollection 2025 May 8.
6
Novel Substituted Cyclic Compounds as SLC6A19 Inhibitors for Treating Phenylketonuria and Other Amino Acidurias.作为治疗苯丙酮尿症和其他氨基酸尿症的SLC6A19抑制剂的新型取代环状化合物
ACS Med Chem Lett. 2025 Apr 11;16(5):734-735. doi: 10.1021/acsmedchemlett.5c00177. eCollection 2025 May 8.
7
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.新型取代苯并咪唑化合物作为用于治疗纤维化疾病，特别是特发性肺纤维化的TLR9抑制剂
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
8
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
9
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.作为用于治疗精神疾病的5-HT2A激动剂的新型吡咯并吡啶化合物。
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.
10
Novel Compounds as Orexin Receptor Agonists for Treating Sleep Disorders, Namely, Narcolepsy and Hypersomnia.用于治疗睡眠障碍（即发作性睡病和发作性嗜睡症）的新型食欲素受体激动剂化合物。
ACS Med Chem Lett. 2024 Jul 3;15(8):1178-1179. doi: 10.1021/acsmedchemlett.4c00285. eCollection 2024 Aug 8.
本文引用的文献
1
5-HT receptors: Pharmacology and functional selectivity.5-羟色胺受体：药理学与功能选择性
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.N，N-二甲基色胺的演变：从代谢途径到脑连接性
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.致幻剂诱导的神经可塑性：全面综述及临床意义探讨
Brain Sci. 2025 Jan 25;15(2):117. doi: 10.3390/brainsci15020117.
4
Exploring DMT: Endogenous role and therapeutic potential.探索二甲基色胺：内源性作用及治疗潜力。
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
5
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.前扣带回皮层中5HT2A受体激活的抗抑郁和抗焦虑作用及其潜在理论机制——现有文献的综述
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
Zotero 插件